Lisata Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lisata Therapeutics Inc 's ROA in the second quarter of 2026?
Lisata Therapeutics Inc recorded a cumulative net loss of $-15 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -67.2%.

However, within the Healthcare sector 715 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4191, from total ROA ranking in the first quarter of 2026 at 4806.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-17.56 %	-51.49 %	-12.93 %	-43.04 %	-40.9 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-15	-16	-17	-18	-19
Return On Assets (TTM)	-67.2 %	-71.52 %	-62.37 %	-65.8 %	-59.44 %
LSTA's Total Ranking	# 4191	# 4806	# 4176	# 4178	# 4194
Total Assets (TTM) in million	21	14	30	22	25
Seq. Total Assets Change	47.53 %	-53.87 %	40.06 %	-13.52 %	-13.18 %
Seq. Net Income Change	-	-	-	-	-

LSTA's 5 Years Annual ROA >> Back to LSTA Management Effectiveness >> Compare LSTA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 328
Sector	# 716
Overall	# 4180

Return On Assets Statistics
High	Average	Low
41.61 %	-45.62 %	-103.16 %
(Mar 31 2018)		(Sep 30 2016)

News about Lisata Therapeutics Inc Return on Assets ROA

Lisata Therapeutics: Overcoming Financial Obstacles to Revolutionize Pancreatic Cancer Treatment

Lisata Therapeutics: Promising Progress in Pancreatic Cancer Treatment Amidst Financial Challenges
Lisata Therapeutics, a renowned biopharmaceutical company, has recently announced a major milestone in its journey towards finding effective treatment options for pancreatic cancer. The company proudly shared the news of successfully enrolling the full cohort for the CENDIFOX trial, a groundbreaking Phase 1b/2a open-label trial conducted in the United States. This trial focuses on evaluating the potential of certepetide, a novel drug, in combination with neoadjuvant FOLFIRINOX-based therapies for treating pancreatic, colon, and appendiceal cancers.
With pancreatic cancer being one of the deadliest types of cancer, accounting for a significant number of cancer-related deaths annually, the enthusiastic enrollment of patients in this trial brings hope to countless individuals and their families. Lisata Therapeutics dedication to furthering medical advancements and unlocking potential breakthroughs in cancer treatment deserves applause.

Financial Statements
Lisata Therapeutics Inc 's Assets	$ 21 million	LSTA's Balance sheet
Lisata Therapeutics Inc 's Income	$ -3 million	Quarterly LSTA's Income Statement
LSTA's Income by Division		See LSTA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-66.3 %	37.64 %	-24.71 %	169.45 %	32.59 %
Total Assets in million	34	101	73	97	36
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-17	-21	-54	-27	-8
Annual Return On Assets	-48.97 %	-20.73 %	-74.25 %	-28.31 %	-22.61 %

LSTA's 5 Years Annual ROA >> Back to LSTA Management Effectiveness >> Compare LSTA ROA to its Competitors

More Return On Assets Ratios
LSTA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LSTA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LSTA's Competitors
Subscribers only: Roa for Lisata Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for LSTA's Customers

You may also want to know
LSTA's Roi	LSTA's Inventory Turnover Ratio	LSTA's Growth Rates	LSTA's Dividend Comparisons
	LSTA's Profitability Ratios	LSTA's Asset Turnover Ratio	LSTA's Dividend Growth
LSTA's Roe	LSTA's Valuation Ratios	LSTA's Financial Strength Ratios	LSTA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T13:54:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.